FINALSPARK
15.5.2024 12:24:29 CEST | Business Wire | Press release
FinalSpark, a pioneering Swiss biocomputing startup, has launched the first-ever online platform enabling global researchers to conduct experiments remotely on biological neurons in vitro. The platform provides around-the-clock access to 16 human brain organoids aimed at developing the world’s first living processor. These bioprocessors, composed of living neurons capable of learning and processing information, consume a million times less power than traditional digital processors, potentially reducing the environmental impact associated with the rising use of computers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515701469/en/
Brain organoids on electrodes (Photo: Business Wire)
Already, three dozen universities have expressed interest in using the platform. In a testament to our commitment to collaboration, FinalSpark has granted free access to nine institutions for Research Use Only. As the demand for our neuroplatform grows, we are prepared to scale up to meet it, all with the shared goal of building the world’s first living processor. “We firmly believe that such an ambitious goal can only be achieved through international collaboration,” asserts Dr. Fred Jordan, co-founder of FinalSpark.
Additional details about the Neuroplatform and the application process for research institutions are available on FinalSpark’s website at https://finalspark.com/neuroplatform. A scientific publication detailing FinalSpark’s Neuroplatform, titled “Open and remotely accessible Neuroplatform for research in wetware computing,” is also available in the journal Frontiers.
The convergence of AI, recent advancements in biology, and stem cell technologies have opened up new horizons in the field of synthetic biology and wetware computing. With the launch of our neuroplatform, we are at the forefront of this exciting journey. "It is an inspiring time to be a researcher," says Dr. Martin Kutter, co-founder of FinalSpark.
About FinalSpark
Founded in 2014 and based in Switzerland, FinalSpark is at the forefront of technological innovation, pioneering the development of bioprocessors — the next generation of digital processors. These groundbreaking bioprocessors utilize human neurons instead of traditional digital processors, marking a significant leap in processing technology.
FinalSpark offers a Neuroplatform that enables companies to conduct remote research on neuronal tissues placed on MEAs, fully supporting electrophysiological experiments. The three-dimensional neuronal structures have a long lifespan, making them suitable for experiments that run for several months.
Keywords: biocomputing, organoid intelligence, wetware computing, neuron, biology, processor, cell culture, artificial intelligence, energy, CO2
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515701469/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company Sign a 3.2 billion SAR Joint Venture Agreement to Develop and Deliver Expo Village14.9.2026 11:42:00 CEST | Press release
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh. The agreement represents the first joint venture milestone for Expo 2030 Riyadh and reinforces itscommitment to partnering with the private sector to unlock economic opportunities and create lasting value, both in the lead-up to the Expo and well beyond the event itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914576734/en/ Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh The Expo Village will provide purpose-built accommodation for Official Participants and delegations within a fully integrated sustainable district. Designed to
Motive Announces Entitlement Server General Availability for iPhone Duo, iPhone 18 Pro and iPhone 18 Pro Max14.9.2026 11:00:00 CEST | Press release
A launch-ready, cloud-native platform that lets operators support the latest iPhone models from day one. Motive, a global leader in mobile device and connectivity management, today announced the general availability of Motive Entitlement Server support for iPhone Duo and the iPhone 18 series. Ahead of Apple’s announcement, Motive invested in the platform capabilities needed to support the new devices at launch. As a result, operators can support the new iPhone product families without waiting for additional platform development. The release provides comprehensive support for entitlement applications aligned with GSMA standards and interoperates with iOS and Android device ecosystems. This includes iPhone Handoff, which lets customers of supported carriers switch seamlessly between two iPhones while using a single phone number. “Apple’s latest announcement marks another important step toward an eSIM-first future,” said Jeevithan Muttu, SVP and General Manager of Device Management at Mot
Venture Global and China Gas Announce New Long-Term LNG Agreement14.9.2026 10:30:00 CEST | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel. “We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom